Product Overview
[Drug Name]
Generic Name: Polycarbophil Calcium Tablets
Trade Name: ZuoLi Polycarbophil Calcium Tablets 0.5g*12 Tablets
Pinyin Code: ZuoLi JuKaBoFeiGaiPian 0.5g*12 Tablets
[Main Ingredients]
The main ingredient of this product is polycarbophil calcium. Chemical Name: 3,4-dihydroxy-1,5-hexadiene cross-linked polyacrylate calcium.
[Properties]
This product is a film-coated tablet that appears white or off-white after removal of the coating.
[Indications/Main Functions]
This product is used to relieve constipation symptoms in patients with irritable bowel syndrome (constipation type).
[Specifications]
0.5g*12 tablets
[Dosage and Administration]
Oral. The usual adult dose is two tablets (1.0g) three times a day. Take with plenty of water after meals. The typical course of treatment is no more than two weeks.
[Adverse Reactions]
See the package insert for details.
[Contraindications]
This product is contraindicated in the following patients: 1. Patients with acute abdominal diseases (appendicitis, intestinal bleeding, ulcerative colitis). 2. Patients who may develop intestinal obstruction after surgery. 3. Patients with hypercalcemia. 4. Patients with kidney stones. 5. Patients with renal insufficiency (except for patients with mild renal insufficiency and those on dialysis). 6. Patients who are allergic to any ingredient in this product. [Precautions] 1. Important reminder: (1) This product is only for symptomatic treatment. (2) If symptoms do not improve after taking this product, stop taking it (usually within 2 weeks). (3) The safety and efficacy of long-term use of this product have not been confirmed. 2. The following patients should use this product with caution: (1) Patients taking active vitamin D (prone to hypercalcemia). (2) Patients using cardiac glycosides (may increase the effect of cardiac glycosides). (3) Patients who are prone to hypercalcemia (may develop hypercalcemia). (4) Patients diagnosed with gastric achlorhydria and those with a history of gastrectomy (the drug may not be able to fully exert its effect). (5) Patients on dialysis and with mild renal insufficiency (the drug may aggravate renal tissue calcification).
